Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).
Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Albert Oriol, Eirini Katodritou, Ka-Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Elena M. van Leeuwen-Segarceanu, Elena Zamagni, Niels W.C.J. van de Donk, Katja Weisel, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl (2025). Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7502.
Article33 days agoB01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL)
Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Irene Attucci, Elena Zamagni, Mark van Duin, M. D’Agostino, Angelo Belotti, Silvia Mangiacavalli, Mariella Grasso, Gloria Margiotta Casaluci, Massimo Offidani, Giovanni Maria De Sabbata, F. Fioritoni, P. Tosi, P. Musto, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl (2025). B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL). , 110(s1), DOI: https://doi.org/10.3324/haematol.2025.s1.12853.
Article33 days agoHigh Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial
Mattia D’Agostino, Mark van Duin, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Daniela Oddolo, Esther de Waal, Enrique M. Ocio, Mark-David Levin, María-Victoria Mateos, Paula F. Ypma, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Annemiek Broijl, Francesca Gay (2025). High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03429-9.
Article33 days agoMM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Pieter Sonneveld, Philippe Moreau, Meletios A Dimopoulos, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Cavo, Wilfried Roeloffzen, Christoph Driessen, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sureda, Carla J. de Boer, Richard G. Carson, Joan Bladé, Mario Boccadoro, Paula Rodríguez‐Otero (2024). MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study. , 24, DOI: https://doi.org/10.1016/s2152-2650(24)01669-0.
Article33 days agoDaratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
Meletios A Dimopoulos, Pieter Sonneveld, Paula Rodríguez‐Otero, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Richard G. Carson, Joan Bladé, Mario Boccadoro, Philippe Moreau (2024). Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs). , 24, DOI: https://doi.org/10.1016/s2152-2650(24)00952-2.
Article33 days ago